AUG 17, 2026 · PHASE 1 TRIAL
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
ClinicalTrials.gov
This is a Phase 1 trial registration with no results reported; it describes a planned dose-escalation and safety study in an early stage of drug development.
Reported
Estimated enrollment348
Phase Ia primary outcomeDose limiting toxicity (DLT), up to 21 days…
Phase Ia primary outcomeMaximum tolerated dose (MTD), up to 21 days…